ArticleGynecologic oncology reports2026
Paclitaxel hypersensitivity reaction rates in gynecologic and medical oncology patients following slow titration protocol: A quality improvement project.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectivea: To assess whether slow infusion of paclitaxel decreases hypersensitivity reaction (HSR) rates. Methods: This was a pre/post-intervention quality improvement study at a single academic-community hybrid institution. This study retrospectively reviewed patients receiving standard rate paclitaxel between 10/2023-10/2024, then implemented a paclitaxel slow infusion protocol (1 mL infusions at rates of 10 mL/h, 20 mL/h, and 30 mL/h, followed by standard rate of 167 mL/h) between 2/2025-8/2025. The primary outcome was HSR rate; secondary outcomes were HSR grade and paclitaxel rechallenge. Descriptive statistics, univariate and multivariate analyses were conducted. Results: A total of 460 patients ( Conclusion: Slow infusion of paclitaxel resulted in significantly more HSRs among all comers. As a result, this institution has resumed standard paclitaxel administration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.